XTL Biopharmaceuticals Ltd. Sponsored ADR ( (XTLB) ) has issued an update.
On March 4, 2025, XTL Biopharmaceuticals Ltd. announced an exclusive sublicense agreement with Biossil Inc., granting them rights to the synthetic peptide hCDR1 for Lupus treatment. This agreement, which includes potential cumulative payments of up to $11.5 million, marks a significant step in XTL’s strategy to monetize its intellectual property assets, potentially enhancing its market position and providing financial benefits through milestone payments.
More about XTL Biopharmaceuticals Ltd. Sponsored ADR
XTL Biopharmaceuticals Ltd. is an intellectual property portfolio company that holds 100% of The Social Proxy Ltd., a web data company. XTL focuses on sublicensing its IP portfolio, particularly surrounding hCDR1 for the treatment of Lupus disease (SLE). The company is publicly traded on the Nasdaq Capital Market and the Tel Aviv Stock Exchange.
YTD Price Performance: -35.03%
Average Trading Volume: 10,588
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $17.08M
For an in-depth examination of XTLB stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com